---
title: "GPCR.US (GPCR.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GPCR.US/news.md"
symbol: "GPCR.US"
name: "GPCR.US"
parent: "https://longbridge.com/en/quote/GPCR.US.md"
datetime: "2026-03-15T12:36:06.741Z"
locales:
  - [en](https://longbridge.com/en/quote/GPCR.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GPCR.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GPCR.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/GPCR.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/GPCR.US/news.md)


# GPCR.US (GPCR.US) — Related News

### [FACTBOX-Top pharma companies racing to launch a weight-loss pill](https://longbridge.com/en/news/278113621.md)
*2026-03-06T13:53:31.000Z*
### [Structure Therapeutics (NASDAQ:GPCR) Price Target Cut to $113.00 by Analysts at Citizens Jmp](https://longbridge.com/en/news/277215398.md)
*2026-02-27T14:33:28.000Z*
> Citizens Jmp has lowered its price target for Structure Therapeutics (NASDAQ:GPCR) from $120.00 to $113.00, maintaining 

### [Structure Therapeutics | 8-K: FY2025 Q4 Revenue: USD 0](https://longbridge.com/en/news/277097848.md)
*2026-02-26T21:19:12.000Z*
### [Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Short Interest Down 17.8% in January](https://longbridge.com/en/news/276080706.md)
*2026-02-16T22:30:21.000Z*
> Structure Therapeutics Inc. (NASDAQ:GPCR) experienced a significant decrease in short interest, down 17.8% in January, t

### [Small molecule blockbuster, is a huge acquisition about to be achieved?](https://longbridge.com/en/news/275316696.md)
*2026-02-09T12:06:17.000Z*
> The dispute between HIMS and Novo Nordisk over oral semaglutide has sparked attention on the oral GLP-1 market. GPCR is 

### [EXCLUSIVE-Hims and Hers Health launches copy of Wegovy pill at $49](https://longbridge.com/en/news/274981798.md)
*2026-02-05T13:30:00.000Z*
### [Piper Sandler Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)](https://longbridge.com/en/news/274971824.md)
*2026-02-05T12:28:23.000Z*
> Piper Sandler has maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR) with a price target of $9